Moreover, a mutant Aa-CdtA variant conjugated to an anti-human CD133-monoclonal antibody led the toxin targeting to CD133+ head and neck squamous-cell carcinomas (Damek-Poprawa et al., 2011). This evidence concerns the gene PROM1 and head and neck squamous cell carcinoma.